Literature DB >> 31353960

Founder effect of the Glu89Gln TTR mutation in the Bulgarian population.

Andrey Kirov1, Stayko Sarafov2,3, Zornitza Pavlova1,4,5, Tihomir Todorov1,4, Teodora Chamova2, Mariana Gospodinova6, Ivailo Tournev2,7, Vanyo Mitev5, Albena Todorova1,4,5.   

Abstract

Hereditary transthyretin amyloidosis is an autosomal dominant genetic disorder caused by missense mutations in the TTR gene resulting in amyloid formation of the transthyretin protein. Depending on the system affection, the manifestations may be different and high heterogeneity in the penetrance is observed. An endemic region in Bulgaria exists where the TTR mutation Glu89Gln is found with high frequency. This is a rare mutation and was probably introduced in the population by a common ancestor. This phenomenon, called "founder effect" was proved in carrier families by haplotype analysis of microsatellite markers showing linkage disequilibrium. Allele frequencies were analyzed and haplotype reconstruction was done with Arlequin v.3.01 software. The common ancestry of the carriers was demonstrated using additional data for their genealogies and microsatellite data from a control group of non-affected individuals. The results show that the mutation Glu89Gln is linked to one haplotype, called "hypothetical founder haplotype" which was compared to published haplotype data from other European patients and no similarity was found. Further population genetics studies of carriers of the Glu89Gln mutation from other endemic regions are required in order to clarify the geographical distribution of the mutation.

Entities:  

Keywords:  Bulgarian population; Founder effect; Glu89Gln mutation; Transthyretin amyloidosis

Mesh:

Substances:

Year:  2019        PMID: 31353960     DOI: 10.1080/13506129.2019.1634539

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  3 in total

1.  Lumbar Spinal Stenosis: A Rare Presentation of Hereditary Transthyretin Amyloidosis.

Authors:  Arman Çakar; Murat Mert Atmaca; Dilcan Kotan; Hacer Durmuş; Feza Deymeer; Piraye Oflazer; Yeşim Parman
Journal:  Noro Psikiyatr Ars       Date:  2020-10-11       Impact factor: 1.339

Review 2.  ATTR Epidemiology, Genetics, and Prognostic Factors.

Authors:  Chukwuemeka A Obi; William C Mostertz; Jan M Griffin; Daniel P Judge
Journal:  Methodist Debakey Cardiovasc J       Date:  2022-03-14

3.  Seven Years of Selective Genetic Screening Program and Follow-Up of Asymptomatic Carriers With Hereditary Transthyretin Amyloidosis in Bulgaria.

Authors:  Teodora Chamova; Mariana Gospodinova; Ognian Asenov; Tihomir Todorov; Zornitsa Pavlova; Andrey Kirov; Sylvia Cherninkova; Kristina Kastreva; Ani Taneva; Stanislava Blagoeva; Sashka Zhelyazkova; Plamen Antimov; Kaloian Chobanov; Albena Todorova; Ivailo Tournev
Journal:  Front Neurol       Date:  2022-04-08       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.